Underdog Pharmaceuticals Announces MD.USE Partnership and Technology Acquisition

Mike-Profile-Pic-1a-o

Underdog Pharmaceuticals Announces MD.USE Partnership and Technology Acquisition

MOUNTAIN VIEW, Calif., Jun. 12, 2020 — Underdog Pharmaceuticals, Inc., a pharmaceutical company designing engineered cyclodextrins to address atherosclerosis and other serious diseases of aging, has completed a partnership and technology acquisition agreement with MD.USE Innovative Solutions, SL.

Underdog is built upon the combined power of computational and synthetic chemistry, and the strength of our computational system derives significantly from our long-standing relationship with MD.USE Innovative Solutions, SL, a start-up from Santiago de Compostela University, Spain. Its founders, Drs Ángel Piñeiro and Rebeca Garcia-Fandino, are experienced computational chemists, and the world’s leading specialists in the development of cyclodextrin-specific simulations.

Underdog has worked with MD.USE over two years to build a new software system, Candymer, which can build and parameterize sophisticated molecular dynamics simulations of cyclodextrin-sterol complexes. With it, we can test drug target interactions, off-target impact, and also design entirely new molecules. It’s critical to Underdog both in the testing and optimization of our lead candidates, now, and in the design of potential new therapies tomorrow.

Modeling a Cyclodextrin – 7KC Interaction with Candymer
Therefore, we are delighted to announce a new relationship with MD.USE, under which Underdog receives ownership of Candymer and a related suite of platform technologies*, exclusive access to their services in our field of interest, and Angel and Rebeca join our team. With this platform and these people, our combined computational team is poised to do great things.
The Underdog computational team: Rebeca Garcia-Fandino, Amelia Anderson and Ángel Piñeiro

* The suite of technologies includes UndARdog AR: an augmented reality (AR) tool allowing users to visualize the complexation between CDs and sterols in an immersive environment.

About Underdog

Underdog Pharmaceuticals, Inc., uses engineered cyclodextrins to address atherosclerosis and other serious diseases of aging.

The development of arterial plaques, or atherosclerosis, drives many diseases including stroke, COPD, and heart disease. It is by far the #1 killer in the world.

Our robust computational chemistry and synthetic chemistry programs were born in the labs of SENS Research Foundation (SRF), the only non‐profit devoted to reversing age‐related disease by addressing their underlying causes.

Our novel molecules attack the core cause of atherosclerosis; the oxidized cholesterol derivatives that inhibit the cardiovascular self-repair system. We can target these derivatives safely and effectively, without interfering with key enzymatic systems; offering the possibility of a new class of drugs that could reverse, not merely treat, this deadly disease.

Our founders, Matthew O’Connor and Michael Kope, were principals of SRF and advocates of genuine rejuvenation biotechnologies. Advisors include world-renowned biomedical gerontologist Aubrey de Grey, and leading cyclodextrin expert Lajos Szente.

Underdog completed its initial seed round for $4,000,000 in November, 2019.

For Underdog: press@underdogpharma.com

Share on facebook
Share on twitter
Share on reddit
Share on linkedin
Share on whatsapp
Share on email

Underdog News:

7-Ketocholesterol in disease and aging

Scientists from Underdog Pharmaceuticals, in conjunction with Professor Jay Jerome of Vanderbilt University Medical Center, have published an article in the journal Redox Biology, covering the role of the toxic biomolecule 7-ketocholesterol, especially in the

Read More »

© 2020 Underdog Pharmaceuticals – ALL RIGHTS RESERVED

Site developed by Moonburn.com

© 2019 Underdog Pharmaceuticals – ALL RIGHTS RESERVED

Site developed by Moonburn.com